| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Chapter | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $271.19M | Series E | 4/9/2026 | $85M | $2.86B | $82.09 | Generation Investment Management, Fifth Down Capital, 8VC, Stripes, XYZ Venture Capital, Addition, Narya Capital, Susa Ventures, Maverick Ventures | ||||
 | Cohere Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $196.1M | Series C | 5/14/2025 | $90M | $724.92M | $13.71 | Temasek, Deerfield Management, Define Ventures, Flare Capital Partners, Longitude Capital, Polaris Partners | ||||
 | Collective Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | $0.16 | -11.11% | -20.00% | $713.28M | Series F | 5/4/2021 | $280M | $1.53B | $0.75 | HCSC, DFJ Growth, Founders Fund, G Squared, Maverick Ventures, NEA, PFM Health Sciences, SoftBank, Sun Life Financial | ||||
 | Freenome | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.35B | Series F | 2/15/2024 | $263.96M | $2.05B | $7.40 | Roche, Andreessen Horowitz, BrightEdge Ventures, ARK Investments, ArrowMark Partners, Artis Ventures, Bain Capital, Cormorant Capital, DCVC, Eventide Asset Management LLC, Intermountain Ventures, Perceptive Advisors, Polaris Partners, Pura Vida Investments, Quest Diagnostics, RA Capital Management, Sands Capital, Section 32, Squarepoint Capital, T. Rowe Price Associates | ||||
 | Healthie | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $39.78M | Series B | 10/15/2024 | $23M | $273.02M | $11.77 | TCV, Birchmere Ventures, Velvet Sea Ventures, Greymatter, Watershed | ||||
 | Mammoth Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $379.07M | Series D-3 | 12/2/2025 | $15M | $1.35B | $13.45 | Undisclosed Investors | ||||
 | Nusano | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $474.68M | Series D-1 | 4/21/2026 | $180M | $655.01M | $1.25 | Undisclosed Investors | ||||
 | Vista.ai | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $41.1M | Series B | 1/14/2026 | $4.7M | $393.05M | $1.30 | Cedars Sinai Health System, Intermountain Health, University of Utah, Temple University, Tampa General Hospital, Khosla Ventures, Bold Brain Capital | ||||
 | Exo | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $43.94M | Series D | 5/28/2025 | $22.09M | $272.82M | $0.86 | Samsung, Sands Capital, Bold Capital, Qubit Health Capital | ||||
 | Innovaccer | Healthcare Healthcare Software | Medium | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | $2.59 | -5.47% | -21.52% | $653.62M | Series F-1 | 1/9/2025 | $153.04M | $3.45B | $7.39 | B Capital Group, Banner Health, Danaher Ventures, Generation IM, Kaiser Permanente, M12 | ||||
 | Komodo Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $587.08M | Series F | 3/31/2025 | $50M | $3.71B | $51.00 | Undisclosed Investors | ||||
 | Mesh Optical Technologies | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $50M | Series A-1 | 2/17/2026 | $37.93M | $253.44M | $16.17 | Thrive Capital, Also Capital, Banner Ventures | ||||
 | RapidSOS | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $250.00K | -- | 1 | Not available | -- | -- | $453.18M | Series D | 11/19/2025 | $93.94M | $1.03B | $1.74 | Apax Partners | ||||
 | SmithRx | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $104.84M | Series C | 1/23/2024 | $60M | $354.68M | $3.76 | Venrock | ||||
 | Blink Health | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $583.89M | Series D | 11/15/2024 | $83.19M | $1.96B | $42.00 | 1789 Capital, Fidelity Investments, 8VC, Cercano Management, Sweetwater Private Equity | ||||
 | Everly Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $674.09M | Series F | 12/27/2021 | $154.68M | $3.5B | $64.45 | Touchdown Ventures, Prysm Capital | ||||
 | Genesis Molecular AI | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $340.28M | Series B-3 | 5/20/2026 | $40M | $806.79M | $9.33 | Incyte | ||||
 | Judi Health | Healthcare Healthcare Providers & Services | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $578.44M | Series F | 9/23/2025 | $252.89M | $3.25B | $13.49 | Wellington Management, General Catalyst, Generation Investment Management, Goldman Sachs, 9Yards Capital, B Capital, Edison Partners, Prime Health Investments, Transformation Capital, Mubadala Capital, RioBlanco Capital, Prime Therapeutics | ||||
 | Lycia Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $278.31M | Series D | 6/10/2026 | $75M | $389.03M | $2.04 | Janus Henderson Investors, Balyasny Asset Management, Adage Capital Management, HBM Healthcare Investments, OrbiMed, Eli Lilly and Company, Franklin Templeton, Invus, RTW Investments, Venrock | ||||
 | Midi Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $251.97M | Series D | 2/3/2026 | $100M | $1B | $10.06 | Goodwater Capital, Foresite Capital, Serena Ventures, Advance Venture Partners, GV, Emerson Collective, SemperVirens, McKesson Ventures, Felicis | ||||
 | Parabilis Medicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $811.88M | Series F | 1/8/2026 | $305.25M | $681.2M | $6.16 | RA Capital Management, Fidelity, Janus Henderson Investors, Frazier Life Sciences, Soleus Capital, venBio Partners, Cormorant Asset Management, Nextech Invest, ARCH Venture Partners, Milky Way Investments, GV, T. Rowe Price, Marshall Wace, General Catalyst, Invus, Farallon Capital Management, Foresite Capital, Rock Springs Capital, HBM Healthcare Investments, Samsara BioCapital, Catalio Capital Management, Sixty Degree Capital, Alderline Group | ||||
 | PathAI | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $255.49M | Series C | 5/19/2021 | $165M | $1.11B | $29.50 | D1 Capital Partners, Kaiser Permanente, General Atlantic, Tiger Global Management, 8VC, Adage, Biospring Partners, General Catalyst, KdT Ventures, Polaris Partners, Refactor Capital, Bristol-Myers Squibb Company, Labcorp, Merck Global Health Innovation Fund | ||||
 | Pathos | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $732M | Series E | 8/21/2026 | $300M | $2.97B | $13.24 | Undisclosed Investors | ||||
 | Smarter Technologies | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $70.97M | Series B | 5/14/2024 | $50M | $341.85M | $16.75 | Transformation Capital, Bessemer Venture Partners, Flare Capital Partners, Floodgate | ||||